India, Sept. 24 -- Viking Therapeutics, Inc. (VKTX) is down 15.20 percent, losing $6.33 to $35.32 on Thursday. The move comes after the biotechnology company priced concurrent offerings of 7.86 million shares at $35.00 per share and $225 million of 2.00 percent convertible senior notes due 2032.
Viking Therapeutics is currently trading at $35.32, down from the previous close of $41.65 after opening at $36.03 on the Nasdaq. The stock has traded between $35.11 and $36.62 during the session, with trading volume at 14.84 million shares versus average volume of 3.00 million shares.
Viking expects net proceeds of approximately $258.2 million from the stock offering and $218.0 million from the notes. The company plans to use the proceeds to adva...